Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIDAS: MRD-Adapted Strategy with Isatuximab-KRD in Newly Diagnosed Multiple Myeloma
NCT04934475Phase 3Active, not recruiting
- Start
- Dec 2021
- Primary completion
- Sep 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of isatuximab in multiple myeloma (MM) (4 arms). Primary endpoint: Negative Minimal Residual Disease Rate at 3 years. Started Dec 2021; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04934475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04934475.